Rayfeng Capital
瑞锋资本
elsewhere's corpus doesn't carry a standalone profile of Rayfeng Capital (瑞锋资本) — it appears only as a co-investor in OriCell Therapeutics' financings: participating in the $70M Series C first tranche announced in January 2026, and again in the $110M pre-IPO round co-led by Qiming Venture Partners in April 2026, alongside QIA, NGS and Yizhuang State Investment . Its founding, team, and strategy are not covered here.
AI-generated — may contain errors, please verify.
Rayfeng CapitalFund
瑞锋资本
渲染中…
Mentioned in 3 articles
Coverage
Daily Token call volume reaches trillions, "Morph Intelligence" closes Series A round | Yunqi Partners
The Token Superfactory Takes Another Step Forward
OriCell Therapeutics Announces $110 Million Pre-IPO Round, Co-Led by Qiming Venture Partners
Global leader in innovative tumor immunotherapy
Oricell Therapeutics Closes First Tranche of $70M Series C to Accelerate Global Development of Solid Tumor CAR-T Therapies
A global leader in innovative tumor immunotherapy
